"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP. In ...

Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

Disitamab vedotin plus toripalimab demonstrated a 63.6% pathologic complete response rate in HER2-expressing MIBC patients. The 12-month event-free survival rate was 92.5%, indicating promising ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

“Both groups benefited, but it would look like earlier is better if we can treat patients with low-volume disease,” says Fred Saad, MD, FRCS In this video, Fred Saad, MD, FRCS, shares key findings ...

ARPIs provide significant survival benefits in younger mHSPC patients, with a 13% improvement in 5-year overall survival and 21% in progression-free survival. The meta-analysis included data from 11 ...

Talazoparib and enzalutamide combination significantly improved overall survival in mCRPC patients compared to enzalutamide and placebo. The TALAPRO-2 study showed a median overall survival of 45.8 ...

Darolutamide demonstrated longer treatment duration and delayed progression to metastatic CRPC compared to enzalutamide and apalutamide in Black and White patients. The DEAR and DEAR-EXT studies ...

"For the MIRAGE trial specifically, we're going to continue following patients and we'll look at [data at] 5 years as well," says Amar U. Kishan, MD. In this video, Amar U. Kishan, MD, shares future ...

Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune ...